Published in J Neurochem on November 28, 2011
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry (2013) 1.18
Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol (2012) 1.17
Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes. Structure (2013) 1.11
Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein. Biochemistry (2013) 1.07
Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? Biochem J (2012) 0.97
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci (2013) 0.92
Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci (2012) 0.92
Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes. PLoS One (2012) 0.87
Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest (2016) 0.87
Substrate recruitment of γ-secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping. EMBO J (2016) 0.86
Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis (2012) 0.86
Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data. Eur J Clin Pharmacol (2013) 0.84
A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One (2015) 0.84
A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease. Front Pharmacol (2013) 0.84
Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol (2013) 0.83
The very many faces of presenilins and the γ-secretase complex. Protoplasma (2013) 0.82
Initial Optimization of a New Series of γ-Secretase Modulators Derived from a Triterpene Glycoside. ACS Med Chem Lett (2012) 0.80
γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ. Eur J Neurosci (2013) 0.78
Modeling of age-dependent amyloid accumulation and γ-secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition. Pharmacol Res Perspect (2013) 0.76
Small molecule suppressors of Drosophila kinesin deficiency rescue motor axon development in a zebrafish model of spinal muscular atrophy. PLoS One (2013) 0.76
Presenilins regulate neurotrypsin gene expression and neurotrypsin-dependent agrin cleavage via cyclic AMP response element-binding protein (CREB) modulation. J Biol Chem (2013) 0.75
Cutting in on a secretase pas de deux. Cell Res (2015) 0.75
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes. J Med Chem (2015) 0.75
Aftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease? J Alzheimers Dis (2013) 0.75
Natural Product and Natural Product-Derived Gamma Secretase Modulators from Actaea Racemosa Extracts. Medicines (Basel) (2015) 0.75
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
A century of Alzheimer's disease. Science (2006) 5.84
Skeletal and CNS defects in Presenilin-1-deficient mice. Cell (1997) 4.50
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27
Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 4.12
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA (2009) 4.02
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Substrate-targeting gamma-secretase modulators. Nature (2008) 3.38
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A (2003) 3.36
Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14
A familial Alzheimer's disease locus on chromosome 1. Science (1995) 3.14
Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A (2000) 3.13
Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol (2000) 2.84
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A (1999) 2.82
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature (2010) 2.80
gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci (2009) 2.49
Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci (2005) 2.48
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry (2000) 2.36
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem (2000) 2.33
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem (2003) 2.31
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem (2003) 2.22
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
Purification and characterization of the human gamma-secretase complex. Biochemistry (2004) 2.18
Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A (2002) 2.16
The many substrates of presenilin/γ-secretase. J Alzheimers Dis (2011) 2.02
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol (2007) 1.81
Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci (2011) 1.76
beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics (2008) 1.74
The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry (2006) 1.70
Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry (1999) 1.67
Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol (2005) 1.65
The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc Natl Acad Sci U S A (2005) 1.59
Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics (2008) 1.55
Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A (1996) 1.52
Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem (2004) 1.51
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J Biol Chem (2003) 1.49
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem (2006) 1.48
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem (2005) 1.45
Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry (2006) 1.41
New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat Cell Biol (2001) 1.40
Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther (2006) 1.36
Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron (1995) 1.35
Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc (2003) 1.33
Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry (2004) 1.32
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther (2007) 1.29
A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. J Med Chem (1998) 1.25
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem (2008) 1.22
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. ACS Med Chem Lett (2010) 1.14
Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. ACS Chem Biol (2007) 1.14
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem (2009) 1.11
The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J Biol Chem (1996) 1.10
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem (2005) 1.07
Inhibition of gamma-secretase activity by helical beta-peptide foldamers. J Am Chem Soc (2009) 1.05
In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. Biochemistry (2003) 1.05
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol (2009) 0.98
Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Ther (2010) 0.97
CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2010) 0.96
Advances in gamma-secretase modulation. Curr Opin Drug Discov Devel (2007) 0.94
Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem (2004) 0.93
Identification of gamma-secretase inhibitor potency determinants on presenilin. J Biol Chem (2007) 0.92
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther (2010) 0.91
Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol (2011) 0.89
Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. J Neurosci (2004) 0.87
Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg Med Chem Lett (2008) 0.87
Amyloid-lowering isocoumarins are not direct inhibitors of gamma-secretase. Nat Cell Biol (2002) 0.86
Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg Med Chem Lett (2009) 0.84
Probing pockets S2-S4' of the gamma-secretase active site with (hydroxyethyl)urea peptidomimetics. Bioorg Med Chem Lett (2004) 0.79
Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation. Neurosci Lett (1995) 0.78